Content Library

Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors

Journal/Conference:

2024-11, ISPOR Europe 2024, Barcelona, Spain

Author(s):

Peffault de Latour R1, Scheinberg P2, Spin P3, Balp MM4, Pannagl K5, Wiyani A6, Somenzi O4, Snellman J4, Wang P3, Steenkamp J3, Kulasekararaj A7 1French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France, 2Hospital A Beneficência Portuguesa, São Paulo, Brazil, 3EVERSANA, Burlington, ON, Canada, 4Novartis Pharma AG, Basel, BS, Switzerland, 5Novartis Pharmaceuticals UK Ltd, London, LON, UK, 6Novartis Pharmaceuticals UK Ltd, London, UK, 7King’s College Hospital NHS, London, UK

Publication Date:

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Condition:

Rare & Orphan Diseases

Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L

Journal/Conference:

2024-11, ISPOR Europe 2024, Barcelona, Spain

Author(s):

Wang P1, Steenkamp J1, Balp MM2, Wiyani A3, Pannagl K4 1EVERSANA, Burlington, ON, Canada, 2Novartis Pharma AG, Basel, BS, Switzerland, 3Novartis Pharmaceuticals UK Ltd, London, UK, 4Novartis Pharmaceuticals UK Ltd, London, LON, UK

Publication Date:

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Condition:

Rare & Orphan Diseases

The Economic and Environmental Burden of Hydrophilic and Hydrophobic IOLs in the UK

Journal/Conference:

2024-11, ISPOR Europe 2024, Barcelona, Spain

Author(s):

O'Boyle D1, Rychlik J2, Wright G2 1Alcon Vision LLC, Sligo, SO, Ireland, 2EVERSANA, Burlington, ON, Canada

Publication Date:

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Condition:

Eye

Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Journal/Conference:

2024-11, ISPOR Europe 2024, Barcelona, Spain

Author(s):

Smyth E1, Sibiga A2, Nehdi AN2, Krishna A3, Kim K2, Coaquira Castro J4, Priedane E5, Zhan L4 1Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK, 2EVERSANA, Burlington, ON, Canada, 3EVERSANA India Private Limited, Mumbai, MH, India, 4BeiGene USA, Inc., Emeryville, CA, USA, 5BeiGene UK, Ltd., London, LON, UK

Publication Date:

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Condition:

Cancer

Coding and Reimbursement Assessment for Potential Acquisition

Radiopharmaceutical Indication Prioritization

Pricing Strategy for Inpatient Therapy

Cardiovascular Disease State Assessment with EVERSANA Management Consulting

The client developed predictive and prognostic tests for determining the risk of cardiovascular disease in various patient groups. Before further investing in product development, the client needed to assess the potential for success in CVD by…

Integrated Brand Planning with EVERSANA MANAGEMENT CONSULTING

Optimizing Patient Journey with EVERSANA MANAGEMENT CONSULTING